NCCN Adds Tafasitamab-cxix to Guidelines for B-Cell Lymphomas

On August 18, 2020, MorphoSys and Incyte announced that the National Comprehensive Cancer Network (NCCN) has included Monjuvi® (tafasitamab-cxix) in its latest Clinical Practice Guidelines update in oncology for B-cell Lymphomas. Specifically, the NCCN Guidelines in the United States now include Monjuvi in combination with lenalidomide with a Category 2A designation as an option for the treatment of previously-treated adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma who are ineligible for autologous stem cell transplant.

Read the corporate press release.

The U.S. Food and Drug Administration granted accelerated approved to Monjuvi in combination with lenalidomide in July 2020. Read the FDA approval announcement.

Posted 8/19/2020